FitzPatrick Margaret M
SEC insider (Form 3/4/5 filer). CIK 0001873879. Director at AN2 Therapeutics, Inc. (ANTX) and 1 other issuer. 12 reported Form 4/5 transactions since Sep 2024; latest on Sep 1, 2026. Located in MENLO PARK, CA.
Companies FitzPatrick Margaret M has filed insider reports for
- AN2 Therapeutics, Inc. (ANTX): Director
- Vistagen Therapeutics, Inc. (VTGN): Director
FitzPatrick Margaret M
CIK: 0001873879
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Sep 1, 2026ANTX
AN2 Therapeutics, Inc.
PurchaseDirect2.1K shares at avg. $5.53$12K - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
23.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
10.4K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
10.4K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
23.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
11.5K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
11.5K shares- - Feb 20, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
20.4K shares- - Sep 9, 2025VTGN
Vistagen Therapeutics, Inc.
AwardDirectNon-Qualified Stock Option (right to buy)
17.6K shares- - May 28, 2025ANTX
AN2 Therapeutics, Inc.
PurchaseDirect8.6K shares at avg. $1.18$10K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 1, 2026 |  ANTX AN2 Therapeutics, Inc. | Purchase | 2,098 | $5.53 | $11,602 | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 23,742 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 10,362 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 10,362 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 23,742 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 11,463 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 11,463 | - | - | Direct |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (Right to Buy) | 20,400 | - | - | Direct |
| Sep 9, 2025 |  VTGN Vistagen Therapeutics, Inc. | Award Non-Qualified Stock Option (right to buy) | 17,600 | - | - | Direct |
| May 28, 2025 | ANTX AN2 Therapeutics, Inc. | Purchase | 8,610 | $1.18 | $10,133 | Direct |
1-10 of 12 transactions